Literature DB >> 9600630

Antihyperalgesic effects of spinal cannabinoids.

J D Richardson1, L Aanonsen, K M Hargreaves.   

Abstract

Cannabinoids have been widely reported to produce antinociception in models such as tail flick and hot plate. However, their role in modulating thermal hyperalgesia is unknown. The potency of some drugs, such as the opioids, increases during hyperalgesia. Thus, we evaluated whether there is a change in the effectiveness of intrathecal cannabinoids with hyperalgesia. Additionally, we evaluated whether cannabinoids could inhibit capsaicin-evoked neurosecretion from isolated rat spinal cord. Our results indicate that 1 fmol anandamide (i.t.) completely blocked carrageenan-induced thermal hyperalgesia. However, anandamide at doses as high as 100 pmol had no effect on thermal latencies in normal animals. Additionally, anandamide inhibited K+- as well as capsaicin-evoked immunoreactive calcitonin gene-related peptide release. Finally, cannabinoid receptors were identified in sensory neurons. Collectively, these results indicate that there is an increased effectiveness of modulation of thermal nociceptive thresholds by spinal cannabinoids during hyperalgesia. This antihyperalgesic effect may be the result of cannabinoid-induced inhibition of neurosecretion from certain primary afferent fibers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600630     DOI: 10.1016/s0014-2999(97)01621-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  47 in total

1.  The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.

Authors:  V Chapman
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus.

Authors:  S J Craib; H C Ellington; R G Pertwee; R A Ross
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

4.  Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Authors:  Katherine E Hanlon; Todd W Vanderah
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

5.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 6.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Preclinical assessment of novel therapeutics on the cough reflex: cannabinoid agonists as potential antitussives.

Authors:  Maria G Belvisi
Journal:  Lung       Date:  2007-10-02       Impact factor: 2.584

8.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

9.  Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons.

Authors:  Gabor Veress; Zoltan Meszar; Dora Muszil; Antonio Avelino; Klara Matesz; Ken Mackie; Istvan Nagy
Journal:  Brain Struct Funct       Date:  2012-05-22       Impact factor: 3.270

10.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.